mcrpc_masterclass_post_event

Post-meeting Evaluation

Your feedback is important to us and will help us improve future meetings. Please complete this brief evaluation form.

Full name

Full Name *

1. After attending this masterclass, how would you rate your understanding of PARP inhibitors in metastatic castration-resistant prostate cancer (mCRPC)? For e.g., familiarity with efficacy data, safety data, etc.

1. After attending this masterclass, how would you rate your understanding of PARP inhibitors in metastatic castration-resistant prostate cancer (mCRPC)? For e.g., familiarity with efficacy data, safety data, etc. *

Extremely familiar	Very familiar	Moderately familiar	Slightly familiar	Not familiar at all
Extremely familiarItem #1 Extremely familiar	Very familiarItem #1 Very familiar	Moderately familiarItem #1 Moderately familiar	Slightly familiarItem #1 Slightly familiar	Not familiar at allItem #1 Not familiar at all

2. How likely would you consider PARP inhibitors as a treatment choice for your patients with BRCA-mutated mCRPC post next-generation hormonal agent (NHA)?

2. How likely would you consider PARP inhibitors as a treatment choice for your patients with BRCA-mutated mCRPC post next-generation hormonal agent (NHA)? *

Very likely	Likely	Unlikely	More data/support is required
Very likelyItem #1 Very likely	LikelyItem #1 Likely	UnlikelyItem #1 Unlikely	More data/support is requiredItem #1 More data/support is required

3. How likely are you to now incorporate genetic testing for prostate cancer in your clinical practice? [on a scale of 1-5, 5 it is part of the standard of care]

3. How likely are you to now incorporate genetic testing for prostate cancer in your clinical practice? [on a scale of 1-5, 5 it is part of the standard of care] *

1	2	3	4	5
1Item #1 1	2Item #1 2	3Item #1 3	4Item #1 4	5Item #1 5

4. Were the case studies discussed at the meeting helpful for understanding the positioning and sequencing of different mCRPC treatments?

4. Were the case studies discussed at the meeting helpful for understanding the positioning and sequencing of different mCRPC treatments? *

Very helpful
Somewhat helpful
Not helpful
Other cases may be of interest

5. Please rate your level of satisfaction with the following aspects of the meeting:

5. Please rate your level of satisfaction with the following aspects of the meeting: *

	Very Satisfied	Satisfied	Unsatisfied	Very Unsatisfied
Content / topics	Very SatisfiedContent / topics Very Satisfied	SatisfiedContent / topics Satisfied	UnsatisfiedContent / topics Unsatisfied	Very UnsatisfiedContent / topics Very Unsatisfied
Speakers	Very SatisfiedSpeakers Very Satisfied	SatisfiedSpeakers Satisfied	UnsatisfiedSpeakers Unsatisfied	Very UnsatisfiedSpeakers Very Unsatisfied
Format	Very SatisfiedFormat Very Satisfied	SatisfiedFormat Satisfied	UnsatisfiedFormat Unsatisfied	Very UnsatisfiedFormat Very Unsatisfied
Overall meeting	Very SatisfiedOverall meeting Very Satisfied	SatisfiedOverall meeting Satisfied	UnsatisfiedOverall meeting Unsatisfied	Very UnsatisfiedOverall meeting Very Unsatisfied

6. Which topic(s) would you like to see covered in future meetings?